Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Q-Linea, Audiocast with teleconference, Q3'24

By Inderes11/5/2024, 12:00 PM
Q-Linea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Stewart Gander
00:00 - 00:14

Go ahead. Hello everyone. Thank you for joining our Q3 presentation for Q-linea AB. Stewart Gander here, the CEO. I'm joined by Christopher Samuelson, my CFO.

Christopher Samuelson
00:15 - 00:16

Hello everyone.

Stewart Gander
00:17 - 29:26

Just a quick note here on the disclaimer for any forward-looking statements that we may make during the presentation. And I'll jump straight into the key messages for today. For overall messages, we’d love for you to take these with you as we exit the call today. Number one, I'll provide more details on our market situation and our approach, highlighting that we are targeting a market potential of between 5 to 7 million annual tests for rapid AST. And we'll talk more about how that breaks down into the hospital segments and lab segments that we are approaching right now. Related to that, we are continuing to accelerate our momentum in the US. We've expanded our commercial pipeline considerably over the past months, and we are approaching the first of our US contracts now, aiming to complete those during this quarter, Q4. Thirdly, we've now confirmed that we've established ourselves at a new and lower cost position, having completed our restructuring that was announced previously. Those costs have been real. Cost savings have been realized at a slightly higher rate than we initially planned, and we continue to observe the costs going forward, anticipating being able to achieve targeted savings in selected areas as we go forward. And fourth, you may have seen the news this morning. We've announced a rights issue that aims to raise up to 225 million crowns to provide us with additional funds to enter the market. That should fund us for at least a year now. We think that this next year is going to be a pivotal one for Q-linea AB, as we see the expansion of our commercial pipeline and the conversion of our first commercially used instruments in the market and initial revenue generation. So I'll spend a bit of time on this call talking through how we see that developing and what you can expect going forward. Just to elaborate a little on some of the highlights from the quarter. So, as I mentioned previously on the commercial side, we have multiple commercial evaluations ongoing in the US. Several of these have already been completed, and we are now entering the contracting phase, as I said, with these customers. That phase can take varying amounts of time, but we are confident that the first of these contracts will be signed during Q4. We also aim to have a dozen or more of these evaluations lined up, so that we can maintain this pace of evaluations through this quarter and into 2025. Worth noting, it was anticipated previously, but we are very happy to have confirmed the decision from CMS in the US for the additional NTAP reimbursement coverage. That's the new technology add-on payment. This is only available for tests run on the Q-linea AB ASTar platform, not available for any other rapid AST platform in the U.S., and will offset up to $97.50 per patient who is covered by eligible Medicare and Medicaid coverage. This is a very significant benefit for Q-linea AB and ASTar. We see this as a strong commitment from CMS in both promoting rapid ASTar into the market and also recognizing the technical and commercial significance of the ASTar proposition compared to others in the field. Looking outside the US, we were happy to confirm an additional unit sold in Italy. So that's three now, over the past several months here, within Italy alone, we have something in the order of a dozen evaluations, either ongoing, near completion, or planned to start. So, we would expect this pace in Italy to continue over the coming months. In addition to that, we've announced that we are in contract negotiations in the UK and in Belgium. So we would expect some good news from customer placements there over the coming months as well. Maybe a final point here on the commercial side, we announced the news of our partnership in both Romania and the Gulf Council countries. So the Middle East, where we have partners that will help us penetrate two of the highest antimicrobial resistance markets in the world, where there's the greatest clinical need, and where we expect both high interest and potential for adoption of the ASTar solution to address that need. Looking more inward, our innovation and product development pipeline has our number one priority on the US side, which is to enter clinical trials for our version two menu in the US. This trial has been set up. We previously announced that we had completed our pre-submission with the FDA. So we are now completing the setup and will move shortly into the trial process. We aim to complete this trial during 2025. In addition to that, we continue with a number of development projects, mainly aimed at improving the ASTar platform. Some notable areas of focus. The additional features will enable us to add further breakpoints, both to cover CLSI breakpoints for markets that require that, for example in the Middle East and others. Also, it will enable customers to potentially customize their breakpoints, as this has been a message we've received from the market from certain users. There are a number of other user experience improvements that we think will further extend the ASTar capabilities and performance in the lab. This is one of the areas where we really think that ASTar shines compared to competitors in the field. So we will continue to focus on making it as simple and usable for our lab technicians. Beyond that, we have several longer-term projects that are still progressing. We've previously highlighted our upcoming expansion into the gram-positive menu, aiming for a future launch that will complement our existing gram-negative offering. On the organizational side, we announced some changes in the executive leadership team, so I would like to take the opportunity to thank both Thomas and Tiziana, who've been instrumental over the past years in bringing ASTar to market. Really helping position Q-linea AB at the forefront of our field. Um, we've entered a number of markets with the support of Thomas, and Tatiana has been tremendous in leading our clinical studies and our clinical work in the market, which has helped to establish the evidence base that we're now bringing forward to customers to motivate the use of rapid AST. Franco Pellegrini, who has been leading our Italian direct sales team, will step into the overall VP of Commercial Operations for the EMEA region going forward. In addition to these moves, we've further strengthened our U.S. in-market team. The principle here is that Jim and I are keeping careful track. Jim Catherine, who leads our U.S. sales team. The principle is to match the resources with the growing pipeline. We've got significant demand here and, in order to manage all those evaluations and the consequent contracting and placement processes, we will continue to add resources as we see those customer evaluations coming through. And then an additional note here, we've extended a long-term incentive program to the staff at Q-linea AB, with the view of sharing in the long-term benefits as Q-linea AB opens up this new market segment that I'll talk to shortly. On the financial side, Christine will speak to this in more detail. So I won't say too much here, just to confirm that we've reduced our operating costs to around 14 million a month. This is below the budget and slightly below where we aimed to come out. As I mentioned after our cost-saving program, we're happy that we will aim to maintain or continue to reduce these costs while also simultaneously shifting resources into the market-facing commercial activities. So this will be a key part of our budgeting efforts going into 2025. And then the aforementioned fundraising initiative, where we've now aimed to raise 225 million SEK to fund our forward journey. So that may be just a quick reminder for anyone who is new here. Um, we are focused on the rapid test market, and the Q-linea AB proposition linked to our ASTar platform really revolves around a few core arguments. Number one, the overall ambition here is to significantly reduce the time to an actionable result for a physician to six hours from the time of the test. This will save lives and improve patient clinical outcomes, notably by getting ahead of the sepsis infection for a patient. It also saves money for hospitals, as these are the most expensive in-hospital costs that we face across our societies, and it reduces the effort needed for labs and physicians in addressing the patient while they wait. In the current standard of care, often two or more days are needed for a result. The instrument itself is extremely easy to use with two minutes or less of hands-on time. Really simple plug-and-play. Uh, interface for the technician. We are the only fully automated, random access platform available in the market that offers comprehensive and highly reproducible test results. So maybe a few words just to orient it. We've spoken about this. I know we've spoken at a high level previously, but it is worth noting that we now see more granularity in the market as we delve deeper into it. So, I'll set the stage here. And I think this is something we can keep coming back to over the coming presentations. So we are obviously focused within the microbiology space, addressing bacteremia patients at large. Initially, we are really focused on bloodstream infection patients within that category. The reason for this focus is that the platform technically wouldn't be capable of addressing a wider range of indications, and we aim to do so over time. But really, the aim is to address the bloodstream infection patients because this is where the most critical, urgent clinical need is today. Um, bloodstream infections are roughly a quarter of the total bacteremia patients. And as I mentioned before, they are the major driver of in-hospital care costs. Our platform right now is designed to address the vast majority of these patients. Currently, our menu, which is a gram-negative menu. Um, it will address around half of those, a little less than half of the patients in total. As I mentioned earlier, we are actively developing a Gram-positive menu that will address the rest. So we have a pipeline here that aims at the highest clinical unmet need. And we will continue to expand the platform to address more and more patients as this platform becomes established. And it is therefore easier for customers to adopt additional indications on a platform they already have. So this is really how we're thinking about it from a patient and needs perspective. Um, and then just some orientation on the market itself. Um, there is a current standard of care. Obviously in this space, this is the AST platforms that take, you know, 48 or more hours in many cases to generate a result. And currently, those platforms produce the bulk of those 25 million or so bacteremia tests annually. This market, we would say, in terms of the addressable component we're aiming at, is something in the order of a billion and a half annually, according to market research. And it's really the pull out of this market as those tests are moved into a new segment that we are creating here, along with some other players in the field. Um, really on the back of this urgent clinical need for a faster response. So this emerging gold standard, as we would call it, with same-day results, is a new segment currently with very limited revenues for any player, and we would consider ourselves to be at the forefront of this segment. And as we think about sizing this opportunity, I mentioned the 5 to 7 million tests per year. We would anticipate that the total costs for hospitals would be something in the order of $100 to $200 per test, depending, of course, on volumes and which market we're in, etc. Therefore, you can get an estimate of what this total market segment will be worth over time. We would expect, you know, at least $500 million to $1 billion. Um, you know, just addressing the core bloodstream infection tests that we're looking at today, this segment will obviously grow as more indications are there. But this is really where the highest clinical need is. So, we see ourselves again at the forefront of opening this segment up. And it is really driven by that underlying high clinical need. And tests will start to migrate there as the technical solution makes itself available. So how does this landscape work in practice? And just to share a little bit more granularity on how we're looking at this and segmenting the market. So, some of you will be familiar that, you know, there are thousands of microbiology labs out there in the world. In the US alone, we would anticipate something in the order of 4,000 to 5,000 labs doing some sorts of tests like this, or at least running blood cultures. The ASTar platform is designed as a fully-automated instrument. It is optimized for labs with more than 1,000 positive blood cultures a year. That is, you know, patients per year. Um, it doesn't say that it wouldn't work in other labs smaller than that, but that's really our sweet spot. So, given that there are already about 1200 to 1500 labs in the U.S., that’s plenty to start with. There are similar numbers in the rest of the world. Our team is currently very focused on addressing the early adopters and high potential users in the US. There are, you know, between 200 to 300 labs in the US that account for more than a quarter of the entire volume in the US market. This makes it more manageable for us to engage with a smaller team in front of the key players in the U.S. market. It's also in these institutions that you find the key opinion leaders, those with whom we've collaborated on some of our early access programs and clinical work, which is now being published. I'll speak to that shortly. And these are really the trendsetters and the ones that the rest of the market looks to, to help determine which new technologies are adopted. So it's this focus on the top, you know, 200 to 300 in the US, for example, that we have right now. I showed this picture last time. This is just a mapping that Jim and the team are using of those initial tranche of focused customers. But just to add a little bit of color on this one. So since our FDA approval at the end of April this year, we've now been in contact with more than half of these institutions. And really, our initial outreach is to determine if the institution is interested in rapid AST. Are they aware of it? I think these days we can comfortably say that the vast majority of institutions, at least of this caliber, are very much aware of rapid AST as a technology space. And therefore, the question really is: Are they currently considering the adoption of rapid AST? And now, after several months of interacting with numerous institutions, we've made significant progress. We are seeing that close to half of them are saying, yes, we want to know more. We are actively reviewing this for our lab, which is very heartening. So what the team then does is very methodically screen these customers through multiple interactions, really looking for a few things. We're looking for fit. Are they an institution where ASTar would work well in their workflow? Typically, for instance, institutions of this size are likely to respond positively because ASTar is very much optimized for medium and high volume labs. But there's a variety of factors we want to understand about their workflow. And then we are looking to confirm the budget availability. I would say initially this is the main sticking point, that labs may not have yet approved the budget to adopt a new technology. And this sometimes leads to us parking the conversation for a while and coming back later. However, there are already several dozen institutions that have confirmed to us that yes, they have the budget and would like to proceed further. So then it's really about screening for that likely purchase timing to make sure that we are sequencing them in the right order for evaluations, because once we move into the evaluation phase, we want to essentially, you know, move straight from there into commercial and full clinical deployment of the solution as quickly as possible. So far, we've got more than a dozen U.S. labs that have either completed, initiated, or are planning evaluations in the very near future. So, you know, we continue to move customers through this pipeline. I'll talk more about that in a second. And we expect the evaluation pipeline to continue to grow in size over the coming months and into 2025. So, how do we think about that funnel? Right. And this is not rocket science, very familiar to anyone in the diagnostics lab equipment space, but just some numbers to kind of orient around. As we consider the pace of development in the market. So what you're seeing here is a typical buying cycle for major lab equipment, which the ASTar system would be. And normally, this process would take, end to end, something between 12 and 18 months. As I mentioned, we're already getting into contracting with several customers, which suggests that they've moved through this much faster, which is true. And we will see customers who do that, especially in the early phase, as there is a great interest in getting rapid AST deployed for the benefit of the patients. But this is a typical timeframe that I would expect to see normalize as we go forward. And some enthusiastic early adopters tend to clear through a little faster. So just to walk this through. So the first phase, and probably the longest and most uncertain of the phases, is this initial customer engagement. This is somewhat a dance where, you know, we've either received the lead through one of our marketing outreach programs or our sales team has reached out to them because they are a priority customer. And then we're going through the process of qualifying them, as I mentioned, for fit, budget, likely purchasing timing, etc. The customers are typically also reviewing the alternate technologies available. So there will be a kind of competitor review. And we will be discussing the benefits of ASTar versus other alternatives for the lab. And really, the point of this phase is to anchor support across all the internal stakeholders for an evaluation. We don't want to get too carried away with one or another stakeholder, because it will typically just stall later on, as they will need to bring everyone along within the hospital who's required to approve it. So we're trying to get all of those on the same page before we go into an evaluation. At this point, the timing is typically determined by budget availability or the lab focus. There may be other priorities that need addressing before they can commence with rapid AST. And we're kind of looking for that timing signal. And it's once we get that, that we then okay with the customer, let's go ahead and start a demo. From here on, it's a relatively standardized process. The demo typically lasts three months, or 60 to 90 days, during which the customer actively uses the instrument in their lab environment. At this stage, we are very involved with our in-field support team on the ground, helping the customer to design that evaluation. If there are any questions on the system or interpretation of the data that they need support with, you know, we are very closely engaged here. And the evaluation, as I said, is pretty routine and standardized. The time frame here is more dependent on the customer's internal review of the data. So they may have completed all of the tests for the evaluation. But they need to pull together that report and again discuss and align on the conclusions with all of those stakeholders in the institution. It's at this point also where institutions with multiple lab sites or reference lab networks may start to engage with the broader set of stakeholders. So, you now talk about your multi-site conversations that are happening. And of course, we very much encourage this because for these institutions, we would like to standardize their rapid assay to an ASTar solution. And while this may take longer at this stage, as we speak with more of those stakeholders, it will speed things up as the subsequent installations can then go ahead without an evaluation. Since they now have a sort of approval, if you will, from the central or the main site that conducted the evaluation. So once you know those results are concluded and the customers come back and say, 'Okay, great.' We got what we expected against the protocol that was established for the evaluation. We then go into the purchasing process and here, of course, the negotiation on commercial terms, we will have talked about those at a high level before we even got started with the evaluation. So they will receive indicative pricing and they will be aware of potential volume benefits and whatnot. But here's where we dot the I's and cross the T's, so to speak, with all of the details. And they need to trigger all their internal decision-making, which may involve legal; for example, it certainly will involve the finance team. Um, and it's this, let's say, iteration and involvement of different types of stakeholders that are outside the lab and clinical environment that typically defines the timeline. Right? It can move very quickly. Um, but in a typical case, it's a couple of months, you know, 2 to 3 months in this phase. And then once we receive a purchase order, we're off to the races, so to speak. The instrument may already be there from the evaluation. Our goal is to achieve a very high conversion rate for evaluations. This, as I mentioned, is a fairly involved process with the customer. So they don't want to conduct an evaluation on something if they're not serious about integrating it into their lab. So there's a good chance it will stay there. But in the event they've sent it back or we've taken it to another location for an evaluation. They will receive an instrument shipped to them. And our team will again help to set that up. Uh, then the main work here is really about integrating this into their core clinical workflow. Our team will assist them in working through their clinical protocols and adjusting them so that whenever a patient with the appropriate indication comes in, the ASTar test will be administered. So, this should be the new standard of care for that lab. Uh, and also it will need to be integrated into a lab information system. And this is again typically the component that determines the timeline. It can either go very quickly and smoothly. If all the resources in the lab are available to do this, it can either go very quickly and smoothly, or it can sometimes take a little longer if they need to get some specialists again on their side, usually to get all the appropriate software and wiring in place. So once that's done, the lab will specify a go-live date. And we would expect that all of the patients who meet their clinical criteria for the ASTar test will now have it administered as standard of care with ASTar. So again, that's typically a 12 to 18 month process. I would expect the average to be around 13 to 15 months over time. And, as I mentioned, since the FDA approval in April, we've now got several customers in that purchase phase of the process here. So you can already assess that we've moved a little faster with several cases. And I would expect that to be the case going into next year. But over time, this will normalize to the sort of standard market average. Um, and you know, what are we looking for in those evaluations? I mean, the customer is looking for a few things. They're looking for the technical performance to match what's described on the packet, essentially. So in our instructions for use document, which is very detailed. So they'll be ensuring that the performance is in line with that. We would always expect that that's the case, since it has been robustly tested in clinical trials. So what they're looking for beyond that is really that the impact of the test is going to be demonstrable in their workflow and clinical environment, matching what we would expect from a rapid test. And the core proposition, as we keep emphasizing, is that it should significantly reduce the time to an actionable result for a physician. And what you're seeing here on the slide is some of the data that was presented at our webinar and was very capably presented by Dr. Yee at George Washington University. We've had several of these now complete in the U.S. And really, the scatter plots all look the same, and they correspond very closely to what we see in similar studies in Europe. And this is because the current standard of care is very difficult to shortcut. It's going to take 48 hours or more to get the results for the patient. And what you very consistently see in these studies is that even the ASTar patients who may have had to wait the longest for a technician to come in, after a night shift or similar situation, if they are not open for a third shift to start it. So that's why you see some of them take longer than others. The ASTar test itself always takes around six hours. So variability is really driven by the customer's lab workflow. But even the slowest of the ASTar patients is going to deliver results many hours, you know, ten-plus hours earlier than the fastest of the current standard of care patients. So? So in any event, essentially every single patient is going to benefit from being run on ASTar versus the current standard of care. So it's this data that they're looking to confirm in their own workflow. And again, work with our team to help optimize their protocols so that we can speed up the time to ASTar results even more. Ultimately, we want all the patients to be delivered in that sort of six-hour range from when the positive blood culture goes off. Um, so I'll conclude there. That's sort of an overall summary of how we see things. I think the main message here is, you know, we're very active in driving that pipeline in the US. The published results from our early access programs really indicate the core argument of ASTar, and we’re expecting to see that in essentially all of the evaluations that we’re running now. So those evaluations should continue to move into contracting. And we'll look forward to announcing those concluded contracts as they come. So with that, Krista, do you want to give some of the financial highlights? Yes.

Christopher Samuelson
29:26 - 38:45

Thank you. Stuart and I will start off by stating a few focus areas in the financial part that will guide you through here; the four focus areas that I will talk a little bit about are our financial status. The rights issue that was press released this morning, our burn rate, our expenses, and the going concern. And I will start off by highlighting some of the events that occurred during the quarter and thereafter. As Stuart has mentioned before, our cost savings are running as planned and are almost in full effect now in Q3, which is really good and helpful for us. Also, the loan facility, I would like to highlight that we have a loan facility from Nexttobe totaling 101.5 million. The existing unutilized facility as of 30th December was 23 million, and then we have 7.5 million at the bank, totaling 30.5 million cash available. The rights issue, which I will talk more about in the next slide, was announced this morning and has secured 80% funding. And the operating result, which is an indication of our cost-saving program. The operating result for the third quarter was -41.2 million, which averages to 13.7 million per month, and the parent company equity. To highlight. Also, the financial status of our parent company is 132.6 million Swedish kronor, and it is supported by the Podler technology, valued at 70 million. That is also one of the main reasons why the parent company equity is higher than the group equity. The rights issue and the bridge loan. It was a press release this morning. There was a lot of information in that press release, including a lot of financial and technical details. And not everyone understands all of it. Once you read through it, I'm happy to answer all the questions about this rights issue afterwards via email or by phone. But here, just a few brief things regarding the rights issue. It's a capital raise of approximately 225 million. As Stuart said before, it's an issue of units, where one unit consists of two common shares and one warrant. And the transaction has been secured to approximately 80%. The subscription price is to be set at 30%. Discount to TERP, which stands for Theoretical Ex-Rights Price, is a volume-weighted average price during the period from 9th of December to 3rd of January, so it's not set yet. So, it will be decided later in this process. And then the subscription period will be in January 2025. Also for you to know this, as I said, this transaction has been secured up to 80% and the guarantee fee is 10% in this transaction. Also important in this total structure is the bridge loan, which will help us get through until we receive the net proceeds from the rights issue transaction in early February. And the total capital raise in this rights issue with warrants depends on several factors, such as subscription level, 80% or higher utilization of the warrants, and share price development. So you cannot say for certain what the total amount in this rights issue will be when you include the warrants as well. But these are the facts we can provide. There are many more facts to read in the press release. As I said, I will take any questions during this call, or you can contact me separately by phone or email. Right. For the third and fourth quarter profit and loss. Not much to say. The operating income from sales is still low. We are still in an early commercialization phase, and we also have a reagent rental model used in Italy and other places in Europe, which obviously reduces the sales volume initially. Over time, it will obviously improve. And then we see, however, that the balance between reagent rental and capital sales will gradually shift, especially as we move into the U.S. Uh, but we will still have the reagent rental model in the future. And it’s a good model. But it will mean that we will not have the upfront sales of the instrument. It will be taken over time. That income, the operating result is -4 to 1.2 as compared to last year, 48.3, which is lower, is better, and the operating result per month on average for the third quarter was 13.7 million. Obviously, thanks to the cost saving program earlier this year, and just by comparing the first half year result, the average monthly operating result was 20.2 million. Then we should note that we incurred 8 to 10 million in restructuring costs. You have to adjust for that one. But still, the cost-saving program is in line with what we have previously communicated. The financial position in the third quarter, as I've said before, we have 7.5 million in cash. And then, in addition to that, we have 23 million unutilized loan facility from the main owner, totaling 30.5 million at the end of September. Looking at the working capital, it has been reduced. It will be even further reduced when sales pick up, but it's lower than at last year's end. So, the 39.6 as compared to the 40,405.6, where obviously the instruments have a large part of that inventory size. The group equity is 21,205.7 compared to the year start of 189.6. And then, just to give you a sense of how this has been spent or burnt for the total period January to September, we had an average of 18.2 million per month. Only for the third quarter. It went down to a 14.1 million decrease in equity. So there you can also see how the cost saving program fits in and the parent company equity, as stated before, is stronger than the group equity, mainly thanks to the valuation of the Podler technology. Future financing. It's obviously a focus area for us, and as I've said before, there is 30.5 million available at the end of the quarter. We also have this rights issue ranging from 224 to 225 million, which is 80% secured, and is part of our future financing plans. And that was sent out earlier today. And then we also have information on our burn rate, which was 13.7 million per month last quarter, and which is based on the savings of 50 million annually, previously communicated. Based on this fact, the board considers the available cash and cash equivalents, along with the unutilized portion of the loan facility and the 80% underwritten ongoing rights issue, sufficient to cover the company's requirements for the activities planned over the next 12 months. Obviously, we also continue to be engaged in other means of financing, including strategic partnership discussions, capitalization of existing assets within Q-linea AB, lowering our operating expenses further, and of course, negotiations with new and existing investors, financiers, and lenders. That was it from the financial side.

Stewart Gander
38:45 - 38:50

Thank you, Christer. So I think with that we can turn it over to questions.

Operator
38:56 - 39:16

If you wish to ask a question, please dial pound five on your telephone keypad. To enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Johan Honoris from Ready. Please go ahead.

Unknown
39:19 - 39:46

Thank you for taking our questions. The first question relates to the number of active systems in testing and evaluation, if that's possible to give. It's clearly been increasing. It's been good momentum. Can you provide a flavor for roughly how many systems are in the testing and validation evaluation stage? It may be compared with a year ago.

Stewart Gander
39:48 - 41:08

Hi, thanks for joining. And thanks for the question. Yeah, I tried to provide some insights there. Um, so you asked how many are in evaluation? Typically, it could take 2 or 3 months. Um, some go longer. So we move the instruments from one location to another. So the number of instruments tied up doesn't correspond exactly to the amount of evaluations we've completed. Um, but I think your question was probably how many evaluations have we completed in total. Right. So, I would say, you know, over its lifetime, we've completed several dozen evaluations of varying sorts, but of most interest to us here today are the evaluations conducted this year. Across the US and Europe, we've either completed or are in the process of completing I would say a dozen or more, and as I mentioned, there are more setups to come. Right. So this pipeline has grown during the past two or three quarters here. And we're getting those evaluations set up going forward. So we've got visibility on another couple dozen, let's say, to be run here over the coming months.

Unknown
41:10 - 41:50

Great. Um, and let's see. Also, it was very good to see that you provided an overview of the timeline and the different stages. And you also alluded to expecting that the probability of a successful outcome of an evaluation would be reasonably high. And does this correspond to recent experience?

Stewart Gander
41:52 - 43:24

Yeah. I mean, the number is not as high yet as it was. We'd all love to see it get higher. Right. But I don't know if it's high enough to call an average. Right. But we would anticipate our win rate overall in competitive deals to be at or above, let’s say, 50%. I would aim for that. We're not the only player in the field. Competitors will take some share, but we can say with confidence that at a technical level, the ASTar is superior to anything in the field. We see that from the criteria of a public tender that have been published. Right. So, there isn't a way that a competitor would score more than us on the technical scoring, and it may come down to the weighting of it if we're more or less at parity. So this really comes down to the commercial terms and how much discount others want to take versus ASTar pricing. You know, at its core in the market. So, we are in the advantageous position of being the superior technical solution. So that said, we fully respect our competitors in the space. Um, they're going to do what they can commercially to take some share. But I would expect ASTar to win more than its fair share of those deals. I think we'll have to give it a few more rounds before we see the averages sort out. But like I said, we're aiming for 50% or more of the win rate in the active commercial discussions.

Unknown
43:27 - 43:49

That's good. That's useful. Thank you. And also on the opex side, the cost savings came in a bit lower than we had expected in Q3. And you alluded to the fact that you haven’t failed to reach the full impact of the cost savings, but probably fairly close to it, I suppose.

Christopher Samuelson
43:50 - 44:17

Yes, I can take that, Stuart. Yeah. I mean, we are fairly close to it. There are still some savings that we can see in the near term here, but we should also be aware that we have to balance those against the commercial build-up in the U.S., for instance. So we are balancing these things, and we will keep the total opex level at this or a lower level. That's what we aim for.

Unknown
44:19 - 44:56

Yeah. And the related matter then is what the later stage of evaluation entails as you progress into negotiation and especially installation, which concerns the sort of support available on the US side. Is that in place, or is that something you need to increase the team for? But of course, if you have a very large number of these cases, of course. But I mean, it's within what can be expected in the near-term. Yeah.

Stewart Gander
44:56 - 46:33

Yes. So, the quick answer is yes, the team is in place on both sides of the Atlantic. So in the US and in Europe, the good thing is that the team can cross support. So if there are periods of intensity, you know, our team from Europe can, for example, support in the US, which they've already done on multiple occasions, and vice versa. So we'll be thoughtful about where and how we add resources going forward. But I see that team, you know, as a global one to support our overall fleet of ASTar in the field. But for the time being, we have the resources in place to support the pipeline. We see, as I mentioned, adding resources on a just-in-time basis, if you will. As we grow the pipeline, we announced the addition of a couple more of our corporate accounts leads in the US who are helping, especially at the front end of that funnel. They drive the process all the way through and continue to engage customers obviously after deployment as well, but especially important in that early stage of the funnel as we engage and build relationships with customers. So that's the big bonus right now that's building up, and as we get more of those into the evaluation phase and installs, we will appropriately add resources into the US. So we've got a game plan for that. It's in our budget planning for next year. And it's speaking to what Krista mentioned about making sure we can appropriately offset costs in our overall cost base, that we can add resources where needed without increasing our overall burn rate.

Unknown
46:36 - 46:56

And, the central question relates to the NCI-designated center that is scheduled to perform an evaluation. These centers tend to be fairly large and probably serve as very good reference sites. When can that be completed, and do you have any others similar in the pipeline?

Stewart Gander
46:56 - 48:43

Yes. Great question. Great question. We're really excited about that. For the time being, we can't disclose the name of the partnership site. Once we're fully deployed and they've run their evaluations and approvals, we hope we can share it because it is a very reputable institution. Um, of note there. I mean, it's part of the National Cancer Institute's network, if you will. Unfortunately, the indication area for sepsis represents an acute need for immunocompromised patients, like those undergoing cancer treatment. Oncology patients, you know, have a high need for this space. We're very pleased at the level of interest here and the potential for ASTar to make a really meaningful impact for that patient community. Um, and, you know, we would hope, obviously, that after a successful evaluation, which we can be confident in, I think, that that will then encourage the rest of the network and oncology centers in general to consider rapid ASTar, and specifically ASTar, as a solution for their lab. That evaluation, I can say, is a standard one. So, it has a 90-day period. During which time they have free use of the instrument, and we've already shipped and installed the instruments. So, we expect that, you know, it will be completed this year, if not, very early next year, and then it will move into the next phase of contracting and all that. Um, provided, of course, that they're satisfied with the evaluation results.

Unknown
48:46 - 49:05

Great. And also, you have a direct contract, including multi-vendor testing. And how common is this when you have direct contract, presumably without any tender process?

Stewart Gander
49:07 - 50:51

Um, it varies. It varies by market. Right. So, tenders are more of a European phenomenon, if you will. The US process is a little different. It's not often that there are fully public tenders. Um, they have a variety of ways to explore the different technical options available to them. Um, they may trial, you know, one or more instruments. Often, it's a sort of desktop review. And they may go to see a reference site to see different technologies in play. They more typically conduct trials to fully evaluate a single system, which they may have determined as a preference. Tenders are more common in Europe, where there are public healthcare systems and more public scrutiny of spending. But even in Europe, you can find institutions that have budgets approved for specific areas and can move directly into a purchasing process. It will still often involve, obviously, a competitive review. They'll look at what technologies are available, but they may not have to conduct a full public tender. So, we expect to see these cases pop up. Um, we've had one in Northern Europe recently, uh, interested in acquiring a couple of systems. So obviously we take them into the funnel and work it through, largely based on the process that I described earlier. So, the fact that they're not tenders does mean that they can sometimes progress quicker, but that's not always the case.

Unknown
50:54 - 51:10

But, without being overly technical, what does the doormat study add to the reference status in terms of analytical and health economics?

Stewart Gander
51:10 - 54:38

Yeah. Great. Great point. So there are a couple of elements of that study that we're really excited about. The essence of that study is essentially twofold. So they're looking to measure specifically the time for a patient to get onto optimized therapy, and how that differs for different patient groups who may have received inappropriate therapy. So one that wouldn't work, or they might have received suboptimal therapy. It may be, for example, using overly broad spectrum antibiotics. So, it will examine antibiotic-specific data to prove the hypothesis that ASTar can significantly improve the time to optimized therapy. And that's a little subtly different from the time to result for a test. Right. So it's actually looking towards that clinical benefit for the patient. So that's even more material, if you will, as a data point for a clinician who wants to see the 'so what' for their patients. So that's one aspect of it. I think the other aspect of the clinical design for this study that's quite exciting is that it is a site with a bit of a hub-and-spoke model. So they have a central lab with different treatment facilities. Treatment facilities. So it's one of these larger networks that you frequently find in the US. Find in the U.S. And they are looking to incorporate a critical component into the study. Of how much time does the bottle take to get from one of its referring sites to the central lab to do the test. The central lab conducts the test. And this has multiple implications here. So. Number one, the benefit of deploying ASTar across all the spoke sites. Will be demonstrated because, the hypothesis is, of course, that bottle transit time has an impact on patient results. Transit time has an impact on patient results. Right. So we will be looking at that. So one conclusion from that would be for a large multi-site institution to say. Okay, I want the ASTar in all the satellite sites as well as the core lab. The other implication for us, which is potentially, down the road, even more interesting, is that there are a lot of distributed, multi-site institutions which may not have the volumes or the technical capacity in microbiologists to deploy in all the remote satellite locations is significant, right? So this will help us underscore the value potential inherent to our tool, which supports the site in not losing time during transport for the incubation of the sample. That is to say, when it comes into the core lab, it will already be closer to its readiness to process than is typically the case. So, for really any country with a geography where you find patients more remote or with a healthcare system with smaller satellite clinics and locations that refer into central core labs. I can mention Sweden, for example. This type of technology with a toddler could potentially be very advantageous. This study will, among the other benefits for clinical impact, also help us to uncover more of the specifics of that transit cost burden that many patients face today.

Unknown
54:40 - 54:47

But it also had some implications for potential commercial partners related to the U.S.

Stewart Gander
54:47 - 54:49

Absolutely. Yeah. Yeah.

Unknown
54:51 - 55:01

Yeah. And also, when do you expect to have the first clinical and commercial ASTar system installed in the US as a reference system?

Stewart Gander
55:03 - 56:10

So, we've, yes. Well, we've got some systems installed and up and running, and to some extent, these are already reference systems. These are communities of known individuals. We are collaborating with some of the leading key opinion leaders in the field. It's no secret to the community in some areas where we are able to cross-refer appropriately for folks to have discussions on the instrument. So to some extent, that's already happening. I mentioned that our first full commercial, start-to-finish commercial discussions, we aim to complete during Q4. Some of those may be reference sites as well. And others will simply want to use the system. So we'll continue to expand our reference library, if you will, or reference partners. But, um, we are already, I think, well served by some of the partners we're working with today.

Unknown
56:13 - 56:50

And to go back to Europe on the rental part of the business model, as that gains traction in terms of numbers, is it possible to make a financial contribution or, what's the word, secure specialty financing for the capital costs on your side? Of course, you need to manufacture and install the systems, even if you receive recurring revenues of a smaller size in these examples.

Stewart Gander
56:51 - 57:06

Yeah. We're very conscious of the working capital implications of expanding the fleet, and we hope to expand it at an increasingly rapid speed. So, Krista, do you want to say a few words about our discussions on that side?

Christopher Samuelson
57:06 - 57:44

Um, on the working capital? Obviously, we have a number of systems in place. So, we are happy to sign on the reagent rental models in Europe. When they come up. We have the capital. But obviously, we are also looking for capital sales. So, this will indeed be a mix. But in Europe, so far, we have mostly the reagent rental model. So. So, that's how it is. And we are very cautious about the working capital, obviously. And we plan that very much in detail going forward.

Stewart Gander
57:46 - 57:47

Yes, I think.

Unknown
57:48 - 57:49

Relating. yeah.

Stewart Gander
57:50 - 58:12

Well, I think you're asking if there's any deal-specific financing that we can arrange. I think that's something that we've explored with you. So, you know, when we get to that appropriate time, we'll give you some more details. I think there are options there. But we haven't yet completed one of these. Yeah.

Unknown
58:12 - 59:11

And finally, you also stated during the call that with a guaranteed amount from the proposed Rights Issue, you expect to have a 12-month run rate. And of course, there are some variable bits and pieces, sales and financials on the rental side, and the number of valuations, interest, and so on. And then you have the warranty. You can get additional support from that come spring. Is it a typo? So to clarify, the 12-month period starts from today, or does it begin upon completion of the rights issue?

Christopher Samuelson
59:11 - 59:39

The 12-month run rate or the going concern that we state in the queue is from the date of the Q3 report, which is the end of September. That's formally how it's done and what we did. Obviously, we are looking for as much funding from the rights issue as possible and from other means as well to take us further. So, the statement we made in the Q3 report has been effective from the 1st of October.

Unknown
59:42 - 60:16

Yes, that's good clarification. And is it something to be said about any flavor of expectations or what's reasonable for the next year in terms of completed evaluations, and even perhaps the number of systems delivered in a very broad ballpark, or is it too early yet?

Stewart Gander
60:18 - 61:21

I think it's still a little early. Um, I think just as we try to get a sense of what the normal speed through that funnel is going to be. Right. So, if I were to make the assessment based on every customer that's already in negotiation, we would anticipate things to be moving very quickly indeed. So, I think we'll have to see a little bit what the norm looks like, and then we can start to give some more concrete projections for instrument placements. I think we'll also need to see what the final win rates are, right? As we discussed before, I would expect to see maybe our primary competitor respond. You know, with the commercial terms that they have available to them. You know, once we start winning too many of the deals, so to speak. So we'll have to see where that kind of shakes out in terms of the commercial side of the negotiation process and how long that takes.

Unknown
61:23 - 61:27

Great. Thank you. That's all from us.

Christopher Samuelson
61:29 - 61:29

Thank you.

Stewart Gander
61:30 - 61:36

Great. Thanks, Johan. Appreciate the questions. Any other questions from the community?

Operator
61:43 - 61:49

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Stewart Gander
61:51 - 62:03

All right. I think we covered it all then. Appreciate everyone’s time. We went a little bit longer this time. But great questions. So appreciate that and look forward to presenting some more good news at our next quarterly report. Thank you.

Christopher Samuelson
62:03 - 62:04

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…